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Background: Acetaminophen (paracetamol) is recommended as the initial pharmacological treatment for
knee or hip osteoarthritis. However, survey and clinical trial data indicate greater efficacy for non-steroidal
anti-inflammatory drugs and cyclo-oxygenase-2 specific inhibitors.
Design: Two randomised, double blind, placebo controlled, crossover multicentre clinical trials, Patient
Preference for Placebo, Acetaminophen or Celecoxib Efficacy Studies (PACES).
Patients: Osteoarthritis of knee or hip.
Intervention: ‘‘Wash out’’ of treatment; randomisation; 6 weeks of celecoxib 200 mg/day, acetamino-
phen 1000 mg four times a day, or placebo; second ‘‘wash out;’’ crossover to 6 weeks of second
treatment.
Measurements: Western Ontario McMaster Osteoarthritis Index (WOMAC), visual analogue pain scale,
patient preference between two treatments.
Results: Celecoxib was more efficacious than acetaminophen in both periods in both studies; WOMAC
and pain scale scores differed at p,0.05 in period II and both periods combined of PACES-a and in
periods I and II and both periods combined in PACES-b, but not in period I of PACES-a. Acetaminophen
was more efficacious than placebo, generally p,0.05 in PACES-b, and .0.05 in PACES-a. Patient
preferences were 53% celecoxib v 24% acetaminophen in PACES-a (p,0.001) and 50% v 32% in PACES-b
(p=0.009); 37% acetaminophen v 28% placebo in PACES-a (p=0.340) and 48% v 24% in PACES-b
(p=0.007). No clinically or statistically significant differences were seen in adverse events or tolerability among
the three treatment groups.
Conclusions: Greater efficacy was seen for celecoxib v acetaminophen v placebo, while adverse events
and tolerability were similar. Variation in results and statistical significance in the two different trials are of
interest.
A
cetaminophen (paracetamol) is recommended as the
initial drug treatment for patients with osteoarthritis
of the knee or hip,1–3 based on: (a) a high level
of gastrointestinal adverse events with non-specific non-
steroidal anti-inflammatory drugs (NSAIDs), the primary
treatment until the 1990s4 5; (b) a perception that acetami-
nophen is safer than these traditional agents 6; (c) clinical
trials which were interpreted to indicate clinical equivalence
of acetaminophen and ibuprofen7 or naproxen.8
In recent years the possible advantages of acetaminophen
for most patients with osteoarthritis have been questioned.9–11
Two patient surveys indicated that most patients rated
NSAIDs as a better treatment than acetaminophen.12 13 A
randomised, double blind, crossover clinical trial indicated
that 57% of patients reported a preference for diclofenac/
misoprostol versus acetaminophen, while 21% preferred
acetaminophen and 22% expressed no preference.14
Reanalysis of clinical trials which were interpreted to show
similar efficacy of acetaminophen and non-steroidal anti-
inflammatory drugs7 8 indicated greater effect sizes for
ibuprofen and naproxen versus acetaminophen, similar to
diclofenac/misoprostol, suggesting that absence of statistical
significance resulted from low numbers of patients.9
A recent report indicated little efficacy of acetaminophen,15
although this study also included relatively few patients.
Acetaminophen in doses of 4 g/day, as recommended for
osteoarthritis by the American College of Rheumatology3
and other organisations, has been associated with a rate
of gastrointestinal adverse events similar to standard
NSAIDs,16 17 although these observations are confounded, in
part, by a likelihood that acetaminophen is given to patients
at highest risk for gastrointestinal events.
An important recent advance has been the development of
cyclo-oxygenase-2 specific inhibitors, which have efficacy
similar to that of non-specific NSAIDs, but fewer gastro-
intestinal adverse events.18 19 A recent study indicated
significantly greater efficacy of rofecoxib than of acetamino-
phen in patients with osteoarthritis, with comparable adverse
events.20 In this report we present the results of two
randomised, placebo controlled, two period, three treatment,
crossover, double blind clinical trials, Patient Preference for
Abbreviations: MDHAQ, Multidimensional Health Assessment
Questionnaire; NSAIDs, non-steroidal anti-inflammatory drugs; SF-36,




Placebo, Acetaminophen or Celecoxib Efficacy Studies
(PACES), in which patients were given two of the three
treatments. Results of both studies are similar, although
variation of results and statistical significance in the two
studies are of interest.
METHODS
Study design
PACES-a and PACES-b had an identical design—a two
period, double blind, double dummy, crossover trial of
celecoxib, acetaminophen, and placebo in patients with
osteoarthritis of the knee or hip. Inclusion criteria were age
45 or greater, radiographic Kellgren-Lawrence grade 2–4, a
score of 40–90 mm on a visual analogue pain scale, and
designation by the treating physician that the patient was a
candidate for long term treatment with a cyclo-oxygenase-2
specific inhibitor drug or an analgesic drug. The primary
exclusion criteria were significant medical comorbidities,
rheumatoid arthritis or other inflammatory arthritis, acute
joint trauma, chronic pain syndrome, expected need for
surgery during the course of the study, oral or parenteral
corticosteroids within 2 months, or intra-articular injections
of hyaluronic acid within 9 months. Women of childbearing
potential were required to use contraception; pregnant or
lactating women were excluded. These studies were approved
by the institutional review boards of all participating study
sites. All patients signed written informed consent before
participation.
Patients were assigned randomly to one of six treatment
sequence groups to receive a sequence of two of three
treatments, each for 6 weeks (fig 1), celecoxib 200 mg/day—
taken in the morning, acetaminophen 1000 mg four times a
day, or placebo. Each patient received a drug and a placebo
or two placebos in each period. All assessments were
conducted using patient and assessor questionnaires, sent
by facsimile to the Pharmacia (Pfizer) data centre in
Markham, Ontario, Canada. Data were entered into a clinical
database using character recognition software; each entry
was verified manually by a clinical data validation specialist
and double checked by a senior validation specialist. Any
discrepancies were sent to the site assessors for clarification
and verification.
Visit 1 was a screening visit to review inclusion and
exclusion criteria and obtain informed consent. Patient
volunteers were given an extensive list of NSAIDs and
analgesic drugs to discontinue and not to take throughout
the study, and began a 3–7 day washout period.
Propoxyphene (Darvon) 65 mg up to four times per day
was given as a rescue analgesic drug; codeine 60 mg or
tramadol (Ultram) 100 mg, up to four times per day, were
provided as alternatives to fewer than 5% of patients if
propoxyphene was poorly tolerated or ineffective. Patients
were instructed not to take any rescue drug within 12 hours
of any visit.
Visit 2 was conducted 3–7 days after visit 1 to randomise
patients and provide the 6 weeks of study drug and placebo
or two placebos for period I. Visit 3 occurred at the end of the
first 6 week treatment period to evaluate period I study drug.
Patients who discontinued in period I before completion of
6 weeks had a visit 3 assessment at the time of discontinua-
tion, and were invited to participate in treatment period II.
Patients who continued had a second 3–7 day washout
period before treatment period II. Visit 4 occurred 3–7 days
after visit 3, at which time 6 weeks of the second study drug
and placebo or two placebos for period II were provided. Visit
5 occurred at the end of period II, or earlier if the patient
chose not to complete period II, to evaluate period II study
drug. Patients were queried at visit 5 about their overall
preference between the two treatments periods.
Patient and assessor questionnaires
Patients completed a standard eight page questionnaire at
each visit, which included a ‘‘disease-specific’’ Western
Ontario McMaster Osteoarthritis Index (WOMAC),21 22 which
contains 24 100 mm visual analogue scales to assess pain,
stiffness, and function, including a general WOMAC and a
WOMAC directed at the primary affected joint indicated by
the patient, a ‘‘general arthritis’’ Multidimensional Health
Assessment Questionnaire (MDHAQ),23–26 which includes
100 mm visual analogue scales to assess pain, global status,
fatigue, and gastrointestinal distress; and a ‘‘generic’’ Short
Form-36 (SF-36) health survey.27 28
Patients also completed a three page questionnaire unique
to each visit to query general status and possible adverse
events. The unique patient questionnaire for the final visit 5
included a query: ‘‘Please compare control of your arthritis
during the first and second study periods,’’ with five response
options, ‘‘much better during the first study period,’’ ‘‘better
during the first study period,’’ ‘‘no difference between the
first and second study periods,’’ ‘‘better during the second
study period,’’ ‘‘much better during the second study period.’’
Responses of ‘‘much better’’ or ‘‘better’’ were merged in the
analyses presented in this report.
Investigators completed unique questionnaires at each
visit, which included the investigator assessment of the
patient’s global status and change in global status on a
100 mm visual analogue scale, as well as a standard report
Figure 1 Summary of protocol of PACES—double blind, double
dummy, clinical trials. Each patient received a drug and a placebo or
two placebos in each period.
932 Pincus, Koch, Lei, et al
www.annrheumdis.com
used by the Food and Drug Administration for adverse
events. The questionnaires are described in greater detail in
the cited references and in the report of a previous study,14 in
which virtually identical questionnaires were used.
Statistical methods
The three major efficacy outcomes were the total WOMAC
score, 100 mm visual analogue pain scale score, and patient
preference for period I treatment versus period II treatment.
The sample size was planned to have at least 0.90 power at
the 0.05 significance level for treatment comparisons of the
total WOMAC score and the 100 mm visual analogue pain
scale during period I for at least 150 patients for each of the
placebo, acetaminophen, and celecoxib groups. Furthermore,
the paired preference comparison would have at least 0.90
power at the 0.05 significance level with at least 100 patients
for each of the two sequences for acetaminophen before/after
celecoxib.
The false positive (or type I) error rate was kept at the
conventional 5% level for the global tests to compare all three
treatments in the study for all three major efficacy outcomes
through a closed testing procedure,29 with a fixed sequence of
tests for which significance at all preceding steps was
required to proceed to the next step. For PACES-a, the order
of testing was total WOMAC for period I, followed by pain
score for period I, and then patient preference response. For
PACES-b the order of testing was patient preference,
followed by the total WOMAC for period I, and pain score
for period I. Pairwise tests between the three treatments were
conducted only if the global test was found to be significant
(which was the case in both studies). These methods for
multiple comparisons essentially made the total WOMAC
score have the primary role in PACES-a and the patient
preference have the primary role in PACES-b.
Secondary end points included patient global assessment,
also measured on a 100 mm visual analogue scale, SF-36
pain scores, MDHAQ activities of daily living scale scores,
investigator assessment of patient global status, and inves-
tigator assessment of patient change in global status. The last
observation carried forward procedure was used to manage
missing data. Sites that enrolled fewer than five patients
were pooled to allow for adjustment for site in the analyses.
Analyses of total WOMAC score, pain score, and paired
patient preference were conducted on three groups: (a)
‘‘intention to treat’’—all patients who received a single dose
of the study drug in period I; (b) ‘‘protocol adherent’’—
omitting patients with major protocol violations such as non-
compliance; (c) ‘‘all completers’’—patients with complete
data for the relevant period(s). Results from all three
analyses were similar. Patient preference results are pre-
sented for patients in the intention to treat population who
provided preference data (requiring participation in both
periods) and for the protocol adherent population. Only the
intention to treat results are presented for all other end
points.
For all six sequence groups, means and their corresponding
standard errors were computed to describe the distribution of
continuous demographic, clinical, and patient/assessor ques-
tionnaire response variables. Distributions of categorical
demographic, patient questionnaire response variables, and
adverse events were described for each group with frequen-
cies and/or percentages. The extent of random imbalances in
Table 1 Demographic, disease, patient questionnaire, and assessor questionnaire measures at screening by sequence group















p Value(n = 121) (n = 114) (n = 60) (n = 115) (n = 57) (n = 57)
A. PACES-a
Demographic measures
Age (years) 63.4 (0.92) 63.5 (0.94) 65.5 (1.28) 62.5 (0.96) 63.7 (1.22) 62.8 (1.30) 0.583
Female (%) 66.1 64 51.7 62.6 59.6 68.4 0.445
Caucasian (%) 90.1 86.0 88.3 88.7 86.0 84.2 0.848
(12 Years of education (%) 50.0 48.2 44.8 42.9 61.8 50.0 0.329
Osteoarthritis measures
Duration of disease (years) 8.4 (0.74) 10.6 (0.80) 10.7 (1.29) 9.0 (0.85) 8.5 (0.97) 8.1 (1.09) 0.093
Radiographic grade (0–4) 2.77 (0.07) 2.76 (0.06) 2.67 (0.09) 2.79 (0.06) 2.75 (0.09) 2.72 (0.10) 0.916
Knee as index joint (%) 85.7 87.5 82.7 81.4 78.5 82.1 0.529
% taking NSAID for OA 68.6 72.8 66.7 67.0 73.7 75.4 0.318
WOMAC target joint (0–100) 47.0 (1.91) 51.6 (1.82) 41.2 (2.30) 45.6 (1.87) 45.0 (2.81) 45.9 (2.67) 0.031
MDHAQ pain VAS (0–100) 53.6 (1.72) 56.5 (1.95) 51.1 (2.47) 55.1 (1.78) 53.8 (2.79) 54.6 (3.16) 0.577
MDHAQ GI distress (0–100) 12.8 (1.70) 19.2 (2.29) 13.5 (2.69) 14.8 (1.81) 10.9 (2.30) 18.7 (3.57) 0.074
(n = 127) (n = 123) (n = 62) (n = 119) (n = 62) (n = 63)
B. PACES-b
Demographic measures
Age (years) 63.9 (0.89) 63.4 (0.80) 62.7 (1.28) 62.8 (0.90) 64.8 (1.31) 63.4 (1.06) 0.708
Female (%) 66.1 63.4 71.0 71.4 62.9 57.1 0.410
Caucasian (%) 86.6 83.7 79.0 90.8 83.9 85.7 0.350
(12 Years of education (%) 46.4 45.5 53.2 44.4 51.6 50.8 0.822
Osteoarthritis measures
Duration of disease (years) 10.5 (0.95) 9.7 (0.75) 8.2 (0.87) 8.3 (0.75) 10.4 (1.32) 9.5 (1.10) 0.589
Radiographic grade (0–4) 2.81 (0.06) 2.86 (0.07) 2.84 (0.10) 2.81 (0.07) 2.94 (0.09) 2.75 (0.10) 0.782
Knee as index joint (%) 85.1 80.5 90.3 83.2 82.2 84.2 0.405
% Taking NSAID for OA 68.5 70.7 71.0 62.2 72.6 63.5 0.356
WOMAC target joint (0–100) 46.3 (1.59) 45.5 (1.84) 47.2 (2.48) 45.3 (1.87) 45.4 (2.43) 46.5 (2.43) 0.997
MDHAQ pain VAS (0–100) 55.0 (1.65) 53.3 (1.97) 53.8 (2.45) 52.3 (1.89) 53.6 (2.70) 52.6 (2.38) 0.945
MDHAQ GI distress (0–100) 14.5 (1.72) 17.5 (1.98) 17.3 (3.27) 14.4 (1.77) 18.0 (2.99) 18.7 (2.92) 0.827
Values are the mean (SE) unless stated otherwise.
VAS, visual analogue scale; GI, gastrointestinal.
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comparisons of the groups at screening visit 1 was described
with p values from a x2/Fisher’s exact test for dichotomous
variables and a Kruskal-Wallis test for continuous variables.
Efficacy of the three treatments was compared for
continuous variables using analysis of covariance for the
change during each of periods I and II, with screening and
baseline scores included as covariates, along with fixed
effects for treatment and centre. Repeated measures analysis
of covariance through generalised estimating equations30
provided supportive analyses for both periods combined.
This method had a full statistical model with covariates for
treatment, period, screening (visit 1), baseline of the patient
(visit 2), and baseline for the period (visit 2 for period I and
visit 4 for period II), with patient as the random sampling
unit. The absence of noteworthy carryover effects for the
residual impact of period I on period II was confirmed
through a corresponding expanded model with their addi-
tional inclusion. Patient preference was assessed using
conditional logistic regression,31 with components for period
and treatment.
The prevalence of adverse events was compared among
treatment groups using conditional logistic regression.
Tolerability was also assessed according to change in a




In PACES-a, 524 patients were enrolled and randomised, and
556 patients were enrolled and randomised in PACES-b
(table 1). No atypical imbalances with p,0.05 were seen in
values at screening between the six sequence groups or
between the three period I treatment groups for age, sex,
race, education level, duration of osteoarthritis, previous
NSAID or analgesic use, proportion of patients who took
aspirin for cardiac prophylaxis, patient identified index joint,
radiographic grade of the index joint, global severity of
osteoarthritis, WOMAC scores, and pain scores (table 1),
other than the WOMAC pain score (p=0.031) in PACES-a.
This latter result is probably spurious relative to multiple
comparisons and is of no consequence, as baseline scores are
covariates in the analyses of covariance for the changes
during periods I, II, and both periods combined. In both
studies all global tests to compare the three groups were
statistically significant (p=0.01 in both) for the three major
efficacy end points, allowing us to proceed to the test for the
respective pairs of treatments. Also, all tests for carryover
effects confirmed their absence.
WOMAC scores
In PACES-a, period I comparisons were addressed as the
prespecified primary end point of that study, with differences
between celecoxib and acetaminophen (p=0.180) and
between acetaminophen and placebo (p=0.080) not sig-
nificant, while differences between celecoxib and placebo
were significant (p=0.002) (table 3A). During period II and
both periods combined, differences between celecoxib and
acetaminophen (p,0.009) and celecoxib and placebo
(p,0.007) were significant, but not between acetaminophen
and placebo (p=0.080 for both periods) (table 3A). In
PACES-b, differences between celecoxib and acetaminophen,
celecoxib and placebo, and acetaminophen and placebo were
all significant (p,0.001 to 0.03) (table 3B). Similarly,
Table 2 Baseline values and changes after 6 weeks of treatment in the WOMAC score and MDHAQ pain and gastrointestinal
distress visual analogue scales at the end of each treatment period in PACES clinical trials
Period I Period II
Celecoxib Acetaminophen Placebo Celecoxib Acetaminophen Placebo
(n = 181) (n = 171) (n = 172) (n = 229) (n = 178) (n = 117)
A. PACES-a
WOMAC target joint
Baseline 48.6 (1.47) 52.8 (1.52) 50.3 (1.60) 49.0 (1.49) 47.5 (1.73) 45.1 (2.15)
Change 210.4 (1.54) 28.4 (1.52) 24.8 (1.66) 28.6 (1.15) 24.5 (1.17) 23.6 (1.36)
% Change* 221.4 215.9 29.5 217.6 29.5 28.0
MDHAQ visual analogue pain scale
Baseline 62.0 (1.11) 67.5 (1.17) 64.0 (1.16) 56.8 (1.64) 54.2 (1.91) 55.1 (2.53)
Change 219.0 (1.91) 217.4 (1.99) 210.5 (1.92) 212.8 (1.56) 25.9 (1.64) 24.9 (2.20)
% Change* 230.6 225.8 216.4 222.5 210.9 28.9
MDHAQ visual analogue patient gastrointestinal distress scale
Baseline 19.2 (1.71) 21.2 (1.82) 19.4 (1.75) 23.3 (1.71) 22.2 (1.87) 18.5 (2.10)
Change 20.9 (1.62) 3.6 (1.91) 2.2 (1.86) 20.3 (1.34) 22.2 (1.40) 4.6 (2.50)
% Change* 24.7 +17.0 +11.3 21.3 29.9 +24.9
(n = 189) (n = 185) (n = 182) (n = 242) (n = 190) (n = 124)
B. PACES-b
WOMAC target joint
Baseline 52.0 (1.29) 51.6 (1.27) 52.5 (1.46) 47.3 (1.47) 47.7 (1.61) 45.0 (1.83)
Change 213.5 (1.36) 28.4 (1.31) 24.6 (1.49) 210.0 (1.17) 24.9 (1.12) 22.4 (1.28)
% Change* 226.0 216.3 28.8 221.2 210.3 25.3
MDHAQ visual analogue pain scale
Baseline 65.2 (1.08) 64.6 (1.24) 64.4 (1.15) 55.8 (1.68) 57.2 (1.81) 54.3 (2.21)
Change 221.8 (1.93) 213.8 (1.74) 27.6 (1.99) 213.0 (1.62) 28.7 (1.75) 22.0 (2.14)
% Change* 233.4 221.4 211.8 223.3 215.2 23.7
MDHAQ visual analogue patient gastrointestinal distress scale
Baseline 22.2 (1.78) 18.7 (1.56) 21.1 (1.87) 25.4 (1.75) 23.7 (1.84) 22.0 (2.39)
Change 21.1 (1.56) 5.0 (1.83) 2.4 (1.76) 23.0 (1.61) 2.4 (1.65) 20.9 (1.72)
% Change* 25.0 +26.7 +11.4 211.8 +10.1 24.1
*This is the percentage of treatment mean change from treatment mean baseline, not mean percentage of individual change from baseline.
Values are the mean (SE) unless otherwise stated.
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statistically significant differences were seen for period II and
both periods combined. Percentage improvements from
baseline in WOMAC scores averaged over all four treatment
periods in PACES-a and PACES-b, were 21.6% for celecoxib
(range 17.6–26.0%), 13.0% for acetaminophen (range 9.5–
16.3%), and 7.9% for placebo (range 5.3–9.5%) (tables 2A
and B).
Pain visual analogue scale scores
Pain VAS results were similar to the WOMAC results (tables 2
and 3). Differences between celecoxib and acetaminophen
were not significant (p=0.193) in PACES-a, period I, while
differences between acetaminophen and placebo (p=0.031)
and celecoxib and placebo (p,0.001) were significant (table
3A). In period II (table 2A, fig 2), differences between
celecoxib and acetaminophen (p=0.003) and celecoxib and
placebo (p=0.002) were significant, while differences
between acetaminophen and placebo (p=0.651) were not
(table 3A). In both periods combined, differences between
celecoxib and acetaminophen (p=0.001), celecoxib and
placebo (p,0.01), and acetaminophen and placebo (p=
0.02) were significant (table 3A). In PACES-b (table 2B, fig 2),
differences in pain scores between celecoxib and acetamino-
phen, celecoxib and placebo, and acetaminophen and placebo
in periods I, II, and both periods combined were significant
(,0.021), other than differences between celecoxib and
acetaminophen in period II (p=0.054) (table 3B).
Percentage improvements from baseline in pain scores
averaged over all four treatment periods in PACES-a and
PACES-b were 27.5% (range 22.5–33.4%) for celecoxib, 18.3%
(range 10.9–25.8%) for acetaminophen, and 10.2% (range
3.7–16.4%) for placebo (tables 2A and B).
Paired patient preference
In the PACES-a ‘‘all completers’’ population, among 173
patients who received celecoxib and acetaminophen, 52.6%
rated celecoxib as ‘‘much better’’ or ‘‘better’’, 24.3% rated
acetaminophen as ‘‘much better’’ or ‘‘better’’, and 23.1%
reported ‘‘no difference’’ (table 4, fig 3). Odds ratios were
2.07 for preference of celecoxib versus acetaminophen
(p,0.001), 2.51 for celecoxib versus placebo (p,0.001),
and 1.21 for acetaminophen versus placebo (p=0.340).
Similar results were seen for the intention to treat and
protocol adherent populations (table 4).
In the PACES-b ‘‘all completers’’ population, odds ratios
were 1.47 for patient preference of celecoxib versus acet-
aminophen (p=0.009), 2.47 for celecoxib versus placebo
(p,0.001), and 1.68 for acetaminophen versus placebo
(p=0.007). Again, similar results were seen for both the
intention to treat and protocol adherent populations (table 4).
Other efficacy end points
In both PACES-a and PACES-b, analyses of the patient global
scale, MDHAQ activities of daily living scale, investigator
assessment of patient global status, investigator assessment
of patient change in global status, and SF-36 pain scores
disclosed patterns similar to those of the primary end points
(data not shown—available on request).
Adverse events
Adverse events were reported by 23–29% of patients in the
three groups. No significant differences were seen between
the proportion of patients reporting any gastrointestinal
event, specifically diarrhoea, dyspepsia, nausea, and flatu-
lence, as well as for upper respiratory infection and headache,
or any event (table 5).
Table 3 Estimated differences (estimate (SEM)) in WOMAC score and MDHAQ pain and gastrointestinal distress visual






placebo p Value Carryover p1
3A. PACES-a
WOMAC target joint
Period I* 22.78 (2.07) 0.180 26.47 (2.06) 0.002 23.69 (2.10) 0.080
Period II 24.03 (1.55) 0.009 24.79 (1.77) 0.007 20.75 (1.85) 0.683
Both periods` 23.41 (1.02) ,0.001 25.50 (1.14) ,0.001 22.09 (1.20) 0.080 0.827
MDHAQ visual analogue pain score
Period I* 23.47 (2.66) 0.193 29.25 (2.63) ,0.001 25.78 (2.68) 0.031
Period II 26.49 (2.17) 0.003 27.66 (2.47) 0.002 21.17 (2.28) 0.651
Both periods` 24.88 (1.50) 0.001 28.90 (1.73) ,0.001 24.02 (1.73) 0.02 0.602
MDHAQ patient gastrointestinal distress visual analogue scale
Period I* 24.83 (2.30) 0.036 22.54 (2.30) 0.269 2.29 (2.33) 0.327
Period II 22.35 (1.47) 0.110 24.97 (1.68) 0.003 22.62 (1.75) 0.136
Both periods` 21.19 (1.22) 0.333 23.16 (1.49) 0.034 21.97 (1.60) 0.217 0.167
B. PACES-b
WOMAC target joint
Period I* 24.99 (1.83) 0.007 29.09 (1.83) ,0.001 24.10 (1.84) 0.027
Period II 24.99 (1.48) ,0.001 26.53 (1.69) ,0.001 21.53 (1.77) 0.387
Both periods` 24.62 (1.00) ,0.001 27.70 (1.12) ,0.001 23.08 (1.10) 0.005 0.937
MDHAQ visual analogue pain score
Period I* 27.69 (2.54) 0.003 213.84 (2.54) ,0.001 26.15 (2.55) 0.016
Period II 24.11 (2.13) 0.054 29.98 (2.43) ,0.001 25.87 (2.54) 0.021
Both periods` 25.87 (1.41) ,0.001 212.24 (1.68) ,0.001 26.38 (1.64) ,0.001 0.614
MDHAQ patient gastrointestinal distress visual analogue scale
Period I* 23.22 (2.16) 0.136 22.54 (2.14) 0.236 0.68 (2.16) 0.755
Period II 24.87 (2.00) 0.015 20.72 (2.29) 0.754 4.15 (2.39) 0.084
Both periods` 23.51 (1.35) 0.009 21.84 (1.30) 0.156 1.68 (1.34) 0.210 0.486
*Results are from an analysis of covariance for visit 3-visit 2 with treatment, visit 1, visit 2, and centre as covariates; results are from an analysis of covariance for
visit 5-visit 4 with treatment, visit 1, visit 4, and centre as covariates; `results are from an analysis using GEE for visit 32visit 2 and visit 52visit 4 with treatment,
period, visit 1, visit 2, baseline as covariates; 1from an analysis using GEE with the model described in footnote ` expanded to include a two degrees of freedom
test for carry over.
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The MDHAQ gastrointestinal distress scale indicated small
changes over 6 weeks for all three treatments in both studies
(tables 2A and B), suggesting no clinically significant gas-
trointestinal intolerability with any of the three treatments.
In PACES-a, eight adverse events were classified as serious
because they required admission to hospital: one in the
celecoxib group—intestinal obstruction and neuropathy;
three in the acetaminophen group—one case of anxiety,
one of cholelithiasis, and one of cholecystitis; and four in the
placebo group—one patient with raised liver function tests,
one with urinary tract malformation and rectal disorder, one
with an accidental fracture, and one with sepsis. Two of the
events, the intestinal obstruction that occurred with the
patient taking celecoxib and increased liver enzymes, which
occurred while a patient was taking placebo, were regarded
by the investigators as potentially related to the study drug.
The other serious adverse events were regarded as probably
not related to the study drug.
Figure 2 Change in scores for WOMAC (A and B) and pain visual analogue scale scores on the MDHAQ (C and D) of patients who received
6 weeks’ treatment with celecoxib, acetaminophen, or placebo, after a 1 week washout period, in PACES-a and PACES-b.
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In PACES-b, four adverse events were classified as serious,
because they required admission to hospital: two in the
celecoxib group—one case of cholelithiasis and one case of
unstable angina; one in the acetaminophen group—chest
pain, probably musculoskeletal in origin, and one in the
placebo group—angina pectoris. All events were considered
unrelated to the study drug by the investigators.
DISCUSSION
The data indicate a gradient of efficacy from celecoxib to
acetaminophen to placebo. Although overall trends in the
two studies are similar, numerical advantages in efficacy of
celecoxib over acetaminophen, and acetaminophen over
placebo according to WOMAC and pain scores in period I of
PACES-a were not significant by the criterion of p,0.05.
Table 4 Patient preferences in PACES clinical three treatment (six sequence) crossover clinical trials in all completers and
protocol adherent patients.
PACES-a PACES-b
All completers Protocol adherent All completers Protocol adherent
Celecoxib v acetaminophen
Prefer celecoxib 91 (52.6) 66 (57.4) 95 (49.5) 84 (52.8)
Prefer acetaminophen 42 (24.3) 24 (20.9) 62 (32.3) 51 (32.1)
No preference 40 (23.1) 25 (21.7) 35 (18.3) 24 (15.1)
OR (SE)* 2.07 (1.18) 2.47 (1.22) 1.47 (1.16) 1.64 (1.18)
p Value* ,0.001 ,0.001 0.009 0.002
Celecoxib v placebo
Prefer celecoxib 71 (52.2) 54 (55.7) 76 (56.7) 62 (59.0)
Prefer placebo 31 (22.8) 24 (24.7) 32 (23.9) 23 (21.9)
No preference 34 (25.0) 19 (19.6) 26 (19.4) 20 (19.0)
OR (SE)* 2.51 (1.20) 2.48 (1.24) 2.47 (1.19) 2.60 (1.23)
p Value* ,0.001 ,0.001 ,0.001 ,0.001
Acetaminophen v placebo
Prefer acetaminophen 31 (37.4) 22 (36.1) 41 (47.7) 29 (44.6)
Prefer placebo 23 (27.7) 18 (29.5) 21 (24.4) 17 (26.2)
No preference 29 (34.9) 21 (34.4) 24 (27.9) 19 (29.2)
OR (SE)* 1.21 (1.22) 1.01 (1.26) 1.68 (1.21) 1.59 (1.24)
p Value* 0.340 0.977 0.007 0.033
Values are the number (%) of patients unless otherwise stated.
*Results are from a conditional logistic regression model with period and treatment as fixed effects and patient as the strata variable; all completers are patients in
the intention to treat group who provided a response for patient preference.
Figure 3 Patient Preference for
Placebo, Acetaminophen or Celecoxib
in PACES-a (A) and PACES-b (B). Each
patient took two of the three treatments
for 6 weeks each. At the final visit, the
patient questionnaire asked: ‘‘Please
compare control of your arthritis during
the first and second study periods,’’
with five response options, ‘‘much
better during first study period,’’ ‘‘better
during first study period,’’ ‘‘no
difference in first and second study
periods,’’ ‘‘better during second study
period,’’ ‘‘much better during second
study period.’’ Patients who responded
‘‘much better’’ or ‘‘better’’ in either
period were merged in these analyses.
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Differences between celecoxib and acetaminophen were
significant in period II and both periods combined in
PACES-a, and periods I, II, and both periods combined in
PACES-b. Patient preference data for celecoxib versus
acetaminophen or placebo were significant in PACES-a and
PACES-b. Patient preference for acetaminophen versus
placebo was significant in PACES-b, but not in PACES-a.
The rate of adverse events was low and similar for
celecoxib, acetaminophen and placebo, with few serious
adverse events. All three treatments were well tolerated at
comparable levels. Although the patient preference inquiry
was based primarily on efficacy, the absence of gastrointes-
tinal intolerability with celecoxib was probably incorporated
by the patients into an assessment of preference.
Greater efficacy of celecoxib compared with acetamino-
phen was also seen using other proposed measures of
improvement in osteoarthritis clinical trials. A 20% improve-
ment criterion proposed by Case et al,15 was seen for WOMAC
scores for three of the four periods with celecoxib, compared
with none of four with acetaminophen or placebo. For the
pain visual analogue scale, the 20% improvement criterion
was met in four of four periods for celecoxib, two of four for
acetaminophen, and none of four for placebo. A 10 mm
change in WOMAC scores proposed by Ehrich et al32 was seen
for celecoxib in period I of PACES-a and both periods of
PACES-b, and was not seen for acetaminophen or placebo in
either trial.
PACES-a and PACES-b are presented as individual, rather
than pooled studies, to illustrate natural variation in results
and p values in two identical clinical trials. Numerical
differences between celecoxib and acetaminophen were
similar in PACES-a and PACES-b. The p value of 0.18 in
PACES-a for differences between celecoxib and acetamino-
phen in period I indicates a result that could occur one in five
times by chance, while the p value in PACES-b of 0.007,
indicates an occurrence less than 1 in 130 times by chance.
The data illustrate that a focus only on the statistical criterion
of p,0.05 value may not necessarily be optimal to discern
differences in the efficacy of one drug versus another.
The PACES clinical trials have several limitations. Firstly,
comparisons between three drugs ideally might be conducted
with each patient taking all three drugs. However, pragmatic
considerations suggested only two treatment periods, but a
design so that three treatments could be compared. Patient
attrition also presents a limitation, as in any clinical trial,
although completion rates for both periods of 73% of patients
in PACES-a and 74% of patients in PACES-b compare
favourably with single period clinical trials in osteoarthritis.
The patient preferences for celecoxib versus placebo or
acetaminophen in this study were similar to those seen for
diclofenac/misoprostol compared with acetaminophen in the
ACTA study,14 and trends are similar to a trial of rofecoxib,
celecoxib, and acetaminophen,33 although responses to
acetaminophen were greater in that trial than in the PACES
trial reported here. The rate of gastrointestinal events was
considerably lower with celecoxib in PACES than with
diclofenac/misoprostol in ACTA. Therefore, the results indi-
cate greater efficacy of celecoxib versus acetaminophen for
patients with osteoarthritis, with similar tolerability and
safety. Although a substantially higher probability is seen
that patients will respond to celecoxib compared with
acetaminophen or placebo, individual variation is seen, as 1
in 3–5 patients expressed a preference for acetaminophen,
and 1 in 3–5 expressed no preference in both trials.
In conclusion, we have found that the efficacy and patient
preference for celecoxib is greater than that for acetamino-
phen, and the efficacy and patient preference for acetamino-
phen is greater than that for placebo. These results may have
implications for an optimal pharmacological approach to the
management of patients with osteoarthritis using drugs
available at this time.
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Table 5 Study-emergent adverse events reported by treatment group for both periods combined* in PACES clinical trials.
Celecoxib Acetaminophen Placebo p Value
A. PACES-a
Patients who took drug (n) 350 300 289
Any event 100 (28.6) 85 (28.3) 76 (26.3) 0.813
Serious events 1 (0.3) 3 (1.0) 4 (1.4) 0.999
Any gastrointestinal event 42 (12.0) 28 (9.3) 26 (9.0) 0.129
Diarrhoea 8 (2.3) 14 (4.7) 4 (1.4) 0.999
Dyspepsia 10 (2.9) 7 (2.3) 3 (1.0) 0.641
Nausea 7 (2.0) 7 (2.3) 5 (1.7) 0.872
Flatulence 8 (2.3) 4 (1.3) 1 (0.3) 0.232
Other
Upper respiratory tract infection 16 (4.6) 17 (5.7) 9 (3.1) 0.3620
Headache 4 (1.1) 11 (3.7) 5 (1.7) 0.872
B. PACES-b
Patients who took drug (n) 373 331 273
Any event 103 (27.6) 87 (26.3) 63 (23.1) 0.423
Serious events 2 (0.5) 1 (0.3) 1 (0.4) 0.999
Any gastrointestinal event 35 (9.4) 30 (9.1) 17 (6.2) 0.500
Diarrhoea 6 (1.6) 11 (3.3) 4 (1.5) 0.870
Dyspepsia 6 (1.6) 6 (1.8) 2 (0.7) 0.999
Nausea 8 (2.1) 4 (1.2) 3 (1.1) 0.329
Flatulence 3 (0.8) 4 (1.2) 1 (0.4) –
Other
Upper respiratory tract infection 7 (1.9) 9 (2.7) 2 (0.7) 0.248
Headache 7 (1.9) 9 (2.7) 7 (2.6) 0.419
*Values are the number (%) of patients reporting at least 1 event. Percentage are based on the number of patients exposed to the drug in either period; p values
are from a conditional logistic regression model with effects for period and treatment.
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